United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $562.82, for a total value of $4,671,406.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $25,423,705.04. This represents a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $565.87 on Friday. The stock’s 50-day simple moving average is $562.78 and its 200 day simple moving average is $511.17. The company has a market cap of $24.02 billion, a P/E ratio of 20.89, a P/E/G ratio of 1.82 and a beta of 0.60. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.63 EPS. As a group, equities analysts predict that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on UTHR shares. Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Morgan Stanley set a $516.00 price target on United Therapeutics in a report on Thursday, May 7th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday. Finally, Bank of America lifted their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $619.42.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently made changes to their positions in the stock. Torren Management LLC bought a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management boosted its stake in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the period. WealthCollab LLC boosted its stake in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. boosted its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $31,000. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.